Search results for "Ulcerative"

showing 10 items of 294 documents

Argon plasma coagulation in the treatment of post-radiotherapy rectal bleeding

2012

Introduction: Chronic radiation proctitis is often associated to radiotherapy for treatment of pelvic cancer. The most common side effect of this pathological condition is rectal bleeding but despite the great number of clinical approaches and techniques that have been employed no consensus for the management of it is available. Although prospective randomized trials about hemorrhagic radiation proctitis are still lacking, endoscopic approach delivering an Argon Plasma Coagulation (APC) seems to be a successful and available option. Patients and Methods: Sixteen patients suffering from post-radiotherapy rectal bleeding were followed. In the nine cases presenting a rectum ulcerative colitis …

Settore MED/18 - Chirurgia GeneraleArgon Plasma CoagulationHemorrhagic radiation proctitiArgon Plasma Coagulation; Hemorrhagic radiation proctitis; Anti-inflammatory therapy; ulcerative colitisAnti-inflammatory therapyulcerative colitis
researchProduct

BONE LOSS I INFLAMMATORI BOWEL DISEASE: OUR MULTICENTRIC STUDY

2011

Patients with inflammatory bowel disease are at increased risk of developing disorder in bone and mineral metabolism. The study was aimed to determine if inflammatory bowel disease (IBD) is a risk factor for osteoporosis in 103 adult patients. We included 103 IBD patients, 67 patients with Crohn's disease (CD) and 36 with ulcerative colitisi (UC). Bone mineral density was measured by dual-energy X-ray absorptiometry. we used T score to express bone loss (osteopenia: -25SD 2 years) and active disease would be risk of bone mineral loss in IBD.

Settore MED/18 - Chirurgia GeneraleCrohn's disease Osteoporosis dexa inflammatory bowel disease ulcerative colitis.
researchProduct

TARGETED THERAPIES FOR INFLAMMATORY BOWEL DISEASES AND COLORECTAL CANCER: AN INCREASING NEED FOR MICROBIOTA-INTESTINAL MUTUALISM

2015

The involvement of intestinal microbiota and dysbiosis in the pathogenesis for inflammatory bowel disease (IBD) and colorectal cancer (CRC) is a well-established factto be taken into real consideration when developing targeted therapies. This review aims to depict how advances in our understanding of the role of intestinal flora in the pathogenesis of IBD and CRC are shaping up the therapeutic protocols of their management. It is demonstrated of their management. It is demostrated that there is a circadian regulation of colocyte gene expression in response to microbiota. Dysbiosis leading to a decrease in microbiome biodiversity is also described in IBD patients in IBD patients whereby thic…

Settore MED/18 - Chirurgia GeneraleSettore BIO/06 - Anatomia Comparata E Citologiacolorectal cancer dysbiosis microbiota inflammatory bowel diseses IBD ulcerative colitis Crohn's disease
researchProduct

NUTRITION IN IBD PATIENTS

2013

Inflammatory Bowel Disease (IBD) is a chronic disorder characterized by a relapsing-remitting course, which alternates between active and quiescent states, ultimately impairing a patients' quality of life.The two main types of IBD are Crohn's disease (CD) and Ulcerative Colitis (UC). CD Shows a transmural granulomatous inflammation that can involve any segment of the intestine affecting all layers of the intestinal wall, while UC is limited to the mucosa and superficial submucosa of the colon. In physiological conditions the gut is costantly exposed to various antigens, commensal microflora and pathogens and the inflammatory response is finely balanced. Anyhow i some individuals with geneti…

Settore MED/18 - Chirurgia GeneraleSettore MED/09 - Medicina InternaIBD Ulcerative Colitis Crohn Disease mesenchymal stem cells murin experimental studySettore BIO/11 - Biologia Molecolare
researchProduct

AMYLOIDOSIS AND INFLAMMATORY BOWEL DISEASE: FACT OR MITH?

2017

Inflammatory Bowel Disease (IBD), which includes both Crohn's Disease (CD) and Ulcerative Colitis (UC), is a chronic idiopathic inflammatory disorder affecting the gastrointestinal tract. Extraintestinal manifestations (EIM) are common in patients with IBD, and occur in 6-47% of patients with CD or UC. EIM can involve organs other than the gastrointestinal tract such as skin, eyes, joints, biliary tract and kidneis. Renal and urinary involvement particularly occurs in 4-23% of patients with IBD. Among the renal complications of IBD, seconfary amyloidosis (AA-type, AAA) is a rare but serious complication. renal amyloidosis has been proven to be the most common lethal manifestation of IBD-ass…

Settore MED/18 - Chirurgia GeneraleSettore MED/12 - GastroenterologiaCrohn' disease Ulcerative Colitis Amyloidisis IBD
researchProduct

An innate cell-mediated, murine ulcerative colitis-like syndrome in the absence of nuclear factor of activated T cells.

2004

Abstract Background & Aims: Nuclear factor of activated T cells transcription factors plays a central role in immunity by regulating the expression of multiple cytokines and other regulatory molecules, many of which have been heavily implicated in the pathogenesis of inflammatory bowel disease. However, few studies have directly investigated the nuclear factor of activated T cells proteins in inflammatory bowel disease. We describe here a specific role for nuclear factor of activated T cells c2 in the pathogenesis of murine inflammatory bowel disease. Methods: Mice deficient for nuclear factor of activated T cells c2, recombinase activating gene-2, or both and transgenic or nontransgenic fo…

T-LymphocytesBiologyInterleukin 21MicemedicineImmune ToleranceCytotoxic T cellAnimalsIL-2 receptorB-LymphocytesImmunity CellularMice Inbred BALB CHepatologyNFATC Transcription FactorsZAP70Innate lymphoid cellGastroenterologyNuclear ProteinsT helper cellRectal ProlapseNatural killer T cellAcquired immune systemMice Mutant StrainsDNA-Binding ProteinsMice Inbred C57BLmedicine.anatomical_structureImmunologyCancer researchColitis UlcerativeTranscription FactorsGastroenterology
researchProduct

Adaptation of TECCU App Based on Patients´ Perceptions for the Telemonitoring of Inflammatory Bowel Disease: A Qualitative Study Using Focus Groups

2020

Background: Despite the continuous adaptation of eHealth systems for patients with inflammatory bowel disease (IBD), a significant disconnection persists between users and developers. Since non-adherence remains high, it is necessary to better understand the patients&rsquo

Telemedicine020205 medical informaticsHealth Toxicology and Mutagenesiseducationlcsh:Medicine02 engineering and technologyArticle03 medical and health sciences0302 clinical medicineNursingCrohn Diseaseinflammatory bowel disease0202 electrical engineering electronic engineering information engineeringeHealthMedicineHumansAdaptation (computer science)E-healthbusiness.industrylcsh:RPublic Health Environmental and Occupational HealthUsabilityInflammatory Bowel DiseasesFocus groupMobile Applicationsdigestive system diseasesClinical trialPatient Compliancefocus groupse-health030211 gastroenterology & hepatologyColitis UlcerativetelemedicineThematic analysisbusinessqualitative researchQualitative researchInternational Journal of Environmental Research and Public Health
researchProduct

The Effect of Probiotics in The Therapy of Ulcerative Colitis - a clinic study -

Ulcerative Coliti
researchProduct

Hypoxia Positively Regulates the Expression of pH-Sensing G-Protein–Coupled Receptor OGR1 (GPR68)

2016

Background & Aims: A novel family of proton-sensing G-proteinâcoupled receptors, including ovarian cancer G-proteinâcoupled receptor 1 (OGR1) (GPR68) has been identified to play a role in pH homeostasis. Hypoxia is known to change tissue pH as a result of anaerobic glucose metabolism through the stabilization of hypoxia-inducible factor-1α. We investigated how hypoxia regulates the expression of OGR1 in the intestinal mucosa and associated cells. Methods: OGR1 expression in murine tumors, human colonic tissue, and myeloid cells was determined by quantitative reverse-transcription polymerase chain reaction. The influence of hypoxia on OGR1 expression was studied in monocytes/macrophages and…

WT wild type0301 basic medicineMM6 MonoMac 6HV healthy volunteerSPARC secreted protein acidic and rich in cysteineNF-κB nuclear factor-κBInflammationBiologyIEC intestinal epithelial cell03 medical and health sciencesIntestinal mucosaTDAG8Ovarian Cancer G-Protein–Coupled ReceptormedicineOGR1 ovarian cancer G-protein–coupled receptor 1 (GPR68)IFN interferonlcsh:RC799-869ReceptorOriginal ResearchTh T-helperInflammationTNF tumor necrosis factorIBD inflammatory bowel diseaseHepatologyRT-qPCR quantitative reverse-transcription polymerase chain reactionAICAR 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranosideTDAG8 T-cell death-associated gene 8 (GPR65)Inflammatory Bowel DiseaseGRP65GastroenterologyHypoxia (medical)Molecular biologyGPR G-protein–coupled receptormRNA messenger RNAIL interleukinChIP chromatin immunoprecipitationHIF hypoxia-inducible factorUC ulcerative colitis030104 developmental biologyHypoxia-inducible factorsCancer researchCD Crohn's diseaselcsh:Diseases of the digestive system. GastroenterologyTumor necrosis factor alphaFCS fetal calf serummedicine.symptomChromatin immunoprecipitationHomeostasisCellular and Molecular Gastroenterology and Hepatology
researchProduct

A real life comparison of the efficacy of adalimumab versus golimumab in moderate-to-severe ulcerative colitis. A multicenter experience from the sic…

2017

Introduction: Adalimumab (ADA) and golimumab (GOL) are effective in the induction and maintenance treatment of moderate-to-severe ulcerative colitis (UC). No comparable data between the 2 drugs are available up to now. Aims & Methods: We reported the Sicilian Network experience on the comparative efficacy of ADA and GOL in patients (pts) with moderate-to-severe UC. From June 2015 until April 2017, 197 consecutive pts with moderate to severe UC were treated with ADA or GOL. The efficacy was evaluated at 8 week and at the end of the follow up considering ‘‘clinical response’’ (reduction of at least 2 points of Partial Mayo Score with concomitant steroid reduction or discontinuation) and “…

adalimumab; golimumab; ulcerative colitis; sicilian network; inflammatory bowel disease; SN-IBDsicilian networkSettore MED/09 - Medicina Internainflammatory bowel diseaseadalimumabSN-IBDgolimumabulcerative coliti
researchProduct